Recently, EHang (Suzhou) Biomedical Co., Ltd. (“EHang Bio”) announced that it has completed the A+ round of financing of tens of millions of yuan. Co-invested by Science and Technology Innovation Investment Partnership (Science and Technology Innovation Fund), Qingzhi Capital (Tsinghua University Intelligent Industry Research Institute Fund), Ruijiang Kangsheng (Kangsheng Global Group Industrial Fund). This round of financing will be used to promote the company’s pipeline research and development and technology platform construction.
EHang Biotech was reorganized and established by the two leading companies in China’s exosome industry – Jiangsu Beger Pharmaceuticals and Shanghai Yibio Biopharmaceuticals. Industrial Park Artificial Intelligence Industrial Park. The company has an exosome isolation platform with independent intellectual property rights and multiple pipelines based on thousands of large-scale multi-center clinical studies, including early blood diagnosis of neurodegenerative diseases, early diagnosis of tumors and late dynamic monitoring. The company’s team and advisory committee include many experts from the International Association for Extracellular Vesicle Research, experts in the fields of neurology and clinical oncology, and experienced industrialization talents. It has exosome technology research and development and 100-level cell exosome production workshop .
EHang has cooperated with many domestic hospitals and academic medical institutions, and has completed over a thousand clinical studies on early blood diagnosis of Alzheimer’s disease and Parkinson’s disease, as well as dynamic follow-up studies on early diagnosis and treatment of over a thousand tumors.
Professor Yin Hang, the founding scientist of EHang Biology, the founding member of the International Association for Extracellular Vesicle Research (ISEV), and a member of the Academic Committee of Tsinghua University, said: “Thanks to the Suzhou Park and new and old investors for their recognition. Continuous empowerment and strong support. “Thousands of scouring is hard work, but blowing away the sand will lead to gold.” Our EHang team is also confident that based on unique innovative technologies and oriented to clinical needs, we will promote the exosome diagnostic screening industry Development. I believe that every persistence will be rewarded, and after the rain, snow and frost, spring will surely usher in the warmth of flowers.”
Dr. Li Zhentao, co-founder and CEO of EHang Biotech, said: “As a leading company in the field of exosomes at home and abroad, the company will continue to promote the research and development of a number of original technologies, and launch a number of innovative products that meet urgent clinical needs as soon as possible to return collaborator trust.
In recent years, Suzhou Industrial Park has insisted on taking the biomedical industry as the “No. 1 industry” facing the future, and has made every effort to build a world-class biomedical industry. At present, it has formed industrial clusters such as innovative pharmaceutical research and development, high-end medical equipment and biotechnology, and has become a domestic development center. One of the highest-level and most competitive biomedical professional parks. At present, the park is striving towards the goal of building a world-class high-tech park, making every effort to create the best innovation ecology, the strongest industrial ecology, and the best business-friendly ecology, so as to escort the development and growth of biopharmaceutical companies. “
Chen Lian, deputy general manager of Suzhou Industrial Park Leading Venture Capital, said: “Biomedicine is a key industry supported and developed by Suzhou Industrial Park. Led by Professor Hang and Dr. Li Zhentao, an expert in the exosome industry, they have gathered top talents in related fields in China and have been deeply involved in this field for many years. Exosome biomarker technology for early diagnosis of neurodegenerative diseases has been clinically proven for many years. We are optimistic that EHang will continue to explore in the field of early diagnosis and screening of cancer and neurodegenerative diseases, and drive the development of exosome technology in the park , to become a leader in the global exosome industry.”
Xiang Chao, a partner of Ruijiang Kangsheng Fund, said: “I am very happy to invest in EHang Biotech. It is always our goal to walk with outstanding founders. We are very optimistic about the field of exosome detection that EHang Biotech is targeting. Its key development The neurodegenerative disease and tumor detection products demonstrated the team’s deep understanding and thinking about the exosome industry, which are extremely valuable and suitable for practical implementation, have a broad market space, and can actually improve the well-being of the people.”
Zhang Yu, managing partner of Qingzhi Capital, said: “The exosome detection track market has broad prospects, but the industrialization and clinical application of exosomes in my country still face many technical challenges. Composed of experts in the field of exosomes and clinicians, they have rich experience in the transformation of the medical device industry and the world’s leading exosome detection technology platform for neurodegenerative diseases. Therefore, we are optimistic about the future development of EHang Biology. After investing in EHang , we will actively empower the company by relying on AIR and Qingzhi Capital’s industry-university-research advantages in the field of AI to help pharmaceutical innovation companies flourish.”
Zhang Peihe, managing partner of Qingnuo Capital, said: “EHang’s team has profound scientific research accumulation and industrialization experience. With its independent platform technology with high technical barriers, it has cooperated with many top domestic hospitals and academic medical institutions to complete the A number of research clinical trials have been carried out, including more than 500 cases of Alzheimer’s disease projects, more than 700 cases of Parkinson’s disease projects, and more than 1,000 samples of early diagnosis studies in multiple early diagnosis fields of tumors. Tsing Nuo Capital is committed to early hard technology The investment platform of EHang has continued to invest and is optimistic about EHang from the very beginning. After reorganizing this year and moving its headquarters to Suzhou Industrial Park, EHang has demonstrated the continuous innovation of leading companies and the team execution ability of fulfilling promises, and entered the scale A new stage of globalization development. Therefore, we will continue to support EHang in its A+ round of financing.”
attached
To view more project information, please go to “Smart Beast Analysis” .
media reports
Arterial Network Arterial Network Yiou Pioneering State
related events
- “EHang Biology” completed tens of millions of yuan in A+ round of financing, jointly invested by Qingnuo Capital, Tianjin Qingzhi, Suzhou Industrial Park Science and Technology Innovation Investment Partnership (Science and Technology Innovation Fund) 2022-12-28
- Chinese intelligent autonomous aerial vehicle manufacturer EHang announces cooperation with Spanish National Police2021-10-08
- EHang’s intelligent autonomous aerial vehicle VT-30 made its public debut: a range of 300 kilometers2021-09-28
- EHang Announces the Latest Progress of Manned Aircraft: It Will Build the EU’s First Air Traffic Terminal in Italy2021-03-17
- EHang responds that it will launch a “UAV with an endurance of over 400 kilometers”: the first test flight will be conducted in the near future2021-03-09
This article is transferred from: https://readhub.cn/topic/8m6C8XJvRzS
This site is only for collection, and the copyright belongs to the original author.